All In Biotech

Drug Trial Radar · NCT06921590

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

A Randomized, Balanced, Phase 1, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

May 9, 2025

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Lead sponsor
Alzamend Neuro, Inc.Industry
Sponsor type
Industry
Collaborators
Massachusetts General Hospital
First posted
Apr 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety and effects of a crystalized form of lithium, AL001, when compared to commonly used Lithium Carbonate in healthy volunteers. The main questions this study aims to answer are: How safe and effective is AL001 when compared to Lithium Carbonate? How is AL001 broken down in the brain and body compared to Lithium Carbonate? Participants will be asked to: * Take both the study drug (AL001) and Lithium Carbonate each for a period of 14 days * Stay overnight at MGH's research unit for two separate 2-week periods * Participate in two separate 24 hour periods of multiple MRIs and blood draws

Conditions

  • Pharmacokinetics
  • Neurology

Interventions

  • AL001Drug

    Crystalized Lithium

  • Lithium Carbonate CapsuleDrug

    Lithium Carbonate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state
  2. To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state
  3. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state
  4. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  5. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  6. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  7. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state
  8. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  9. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  10. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  11. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  12. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  13. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  14. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  15. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  16. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  17. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  18. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  19. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  20. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  21. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  22. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  23. To characterize AL001 lithium PK under the conditions of this studyTime frame: From time zero to the end of the 24 hour 3-dose interval at steady state.
  24. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to end of follow-up period at Day 42(P2)
  25. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to Day 23 (P2)
  26. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to Day 23 (P2)
  27. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to Day 23 (P2)
  28. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to Day 23 (P2)
  29. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to Day 23 (P2)
  30. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.Time frame: From enrollment to Day 23 (P2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.